SCHEDULE: State Street Discloses 5.7% Stake in Kura Oncology
Beneficial Ownership Disclosure
State Street Corporation has reported a 5.7% beneficial ownership stake in Kura Oncology Inc. common stock as of December 31, 2025.
Summary
- State Street Corporation, a Massachusetts-based parent holding company, beneficially owns 4,931,090 shares of KURA ONCOLOGY INC common stock.
- This ownership represents 5.7% of the total class of securities.
- State Street Corporation holds shared voting power over 4,697,657 shares and shared dispositive power over all 4,931,090 shares.
- The filing was made under Rule 13d-1(b), indicating that State Street Corporation is an institutional investor filing in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Subsidiaries involved in the beneficial ownership include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership by a large institutional investor and does not contain performance or forward-looking statements from the issuer.
Industry Context
StockSavvy.ai notes that the disclosure of a significant stake by a major institutional investor like State Street Corporation in a biotechnology company such as Kura Oncology Inc. can signal institutional confidence in the company's long-term prospects, particularly given the capital-intensive nature and regulatory hurdles of the biotech sector. Such filings are routine for large asset managers who hold diversified portfolios.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may positively influence investor sentiment and perception of the company's stability and investment appeal.
- Investment Professionals: Provides transparency regarding institutional ownership, which is a key data point for market analysis and investment strategies.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires filing of this statement (reporting period end date) |
| 02/09/2026 | Date of filing signature by Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer |
Keywords
Kura Oncology Inc, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.